14 CPD points are allocated to the conference in accordance with the CPD scheme of the Royal College of Radiologists.
Programme
Day 1
27 Jan 2020
Day 2
28 Jan 2020
Opening
Professor Mitch Dowsett & Baroness Delyth Morgan
Baroness Delyth Morgan
Professor Mitch Dowsett
Highlights of the last year
BASIC RESEARCH
Ingunn Holen
TRANSLATIONAL RESEARCH
Nicholas Turner
PRIMARY DISEASE
Andrew Wardley
ADVANCED DISEASE
David Miles
CHAIRS: Julia Gee and Andrew Tutt
Professor Nicholas Turner
Professor Andrew Wardley
Professor Ingunn Holen
Keynote Lecture: Philip Poortmans
PERSONALISED BREAST RADIATION THERAPY – ARE WE THERE YET?
CHAIR: Charlotte Coles
Dr Philip Poortmans
Demystifying partial breast irradiation
WHY AND HOW TO DO IT?
Anna Kirby
DOES IT WORK AND WHO SHOULD HAVE IT?
Charlotte Coles
IS LESS REALLY LESS?
Philip Poortmans
CHAIRS: Charlotte Coles & Philip Poortmans
Dr Philip Poortmans
Dr Anna Kirby
Professor Charlotte Coles
Big data in breast cancer
INTRODUCTION: THE CURRENT UK LANDSCAPE
David Dodwell
INVASIVE BREAST CANCER AFTER SCREEN-DETECTED DCIS IN ENGLAND
Gurdeep Mannu
TWENTY FIVE YEAR RISKS OF BREAST CANCER MORTALITY IN 500,000 WOMEN
Carolyn Taylor
ENDOCRINE THERAPY IN THE PRIMARY CARE PRESCRIPTION DATASET
Kieran Horgan
CHAIRS: David Dodwell & Sophia Turner
Mr Kieran Horgan
Dr Gurdeep Mannu
Dr David Dodwell
Dr Carolyn Taylor
Why can’t we kill ER+ breast cancer?
RESISTANCE MECHANISMS TO ENDOCRINE THERAPY
Andy Sims
RESISTANCE MECHANISMS TO CDK4/6 INHIBITION
Ben O’Leary
NEW PROSPECTS FOR KILLING ER+ BREAST CANCER CELLS
Matthew Ellis
CHAIR: Jason Carroll & Stephen Johnston
Dr Matthew Ellis
Dr Andy Sims
Dr Ben O’Leary
Managing the side-effects of endocrine therapy
MANAGING THE SEXUAL IMPACT OF ENDOCRINE THERAPY
Isabel White
HOT FLUSHES
Debbie Fenlon
IMPACT ON TREATMENT ADHERENCE
Mike Dixon
CHAIRS: Adrienne Morgan & Anne Armstrong
Dr Isabel White
Professor Mike Dixon
Professor Deborah Fenlon
SATELLITE SYMPOSIA: EXACT SCIENCES
Prognosis is not enough when making treatment decisions for patients with early breast cancer
Chaired by
Dr Eric Winer, Director of the Breast Oncology Center, Dana-Farber Cancer Institute, Boston
Speakers
Dr Mark Harries, Consultant Medical Oncologist, Guy’s & St Thomas’ NHS FT
Dr Mark Verrill, Consultant Medical Oncologist, The Newcastle Upon Tyne Hospitals NHS FT
Mr Simon Holt, Consultant Surgical Oncologist, Peony Breast Care Unit, Llanelli
Professor Eric Winer
12:55-13:55
Hall 8
SATELLITE SYMPOSIA: ROCHE
Immune Checkpoint Inhibition in Metastatic Triple Negative Breast Cancer
Chair: Professor Peter Schmid
Speakers:
Prof. Javier Cortés
& Dr Melissa Phillips
12:55-13:55
Hall 11
SATELLITE SYMPOSIA: PFIZER
Improve outcomes for HR+/HER2- breast cancer patients: a multidisciplinary case-based discussion
Welcome and Introduction: Dr Alistair Ring, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust
A patient with locally advanced breast cancer: what is the role of Ibrance®q(palbociclib)?
Mr. Henry Cain, Oncoplastic Breast Surgeon, The Newcastle upon Tyne Hospitals NHS Foundation Trust
A patient with metastatic breast cancer, who progressed on adjuvant endocrine treatment: where Ibrance®q(palbociclib) is now an option
Professor Christopher Poole, Consultant Medical Oncologist, University Hospitals Coventry and Warwickshire NHS Trust
A patient with high burden metastatic breast cancer including visceral metastasis: what factors influence the choice of treatment?
Dr. Alistair Ring & Ms. Claire Ryan, Macmillan Nurse Consultant Metastatic Breast Cancer, Maidstone and Tunbridge Wells NHS Trust
Panel discussion
Keynote Lecture: Matthew Ellis
TREATMENT-DEPENDENT BREAST TUMOUR EVOLUTION
Matthew Ellis
CHAIR: Sarah Pinder
Dr Matthew Ellis
Special issues in managing metastatic disease
PATIENT SPECIFIC TREATMENT SEQUENCING IN ER+ ADVANCED BREAST CANCER
Stephen Johnston
WHOLE BODY MRI IN THE MANAGEMENT OF BONE METASTASES
Anwar Padhani
IS TREATMENT OF OLIGOMETASTASES CURATIVE?
Andreas Makris
CHAIRS: Sarah Vinnicombe & Ian Smith
Professor Stephen Johnston
Dr Andreas Makris
Phenotypic and genotypic heterogeneity
GENOMICS OF INVASIVE LOBULAR BREAST CANCER
Christine Desmedt
GENOMIC LANDSCAPE OF BREAST CANCER METASTASIS AND RELAPSE
Adrian Lee
MOLECULAR EVOLUTION OF LYMPH-NODE SPREAD IN EARLY BREAST CANCER – A SURGEON’S INTEREST
Peter Barry
CHAIRS: Adrian Lee & Julia Gee
Mr Peter Barry
Dr Adrian Lee
Professor Christine Desmedt
DCIS – Risk estimates and management
MOLECULAR FEATURES OF DCIS AND INVASIVE BREAST CANCER
Elinor Sawyer
ADDRESSING OVERTREATMENT OF SCREEN DETECTED DCIS; THE LORIS TRIAL
Matthew Wallis
NEERA PATEL LECTURE: BREAST CANCER-RELATED DEATHS IN DCIS: THE DUTCH EXPERIENCE
Jelle Wesseling
CHAIRS: Sarah Pinder & Lynda Wyld
Professor Elinor Sawyer
Professor Jelle Wesseling
Dr Matthew G Wallis
14:35-15:55
Hall 11
Free Communications 1
Chairs: Mark Sibbering & Lesley Turner
1)
10-year results of the International Breast cancer Intervention Study II (IBIS-II)
Jack Cuzick et al
2)
Ethnicity and the surgical management of early invasive breast cancer in over 137 000 women in England
Toral Gathani et al
3)
Surgical outcomes following neoadjuvant chemotherapy – a UK national prospective multi-centre cohort study Stuart A McIntosh et al
4)
Retesting of receptors status (ER, PR and HER2) and proliferation biomarkers (Ki67 and SPAG5) after receiving neoadjuvant chemotherapy (NACT) should be mandatory to guides the choice of the optimal adjuvant therapy in Breast Cancer (BC)
Tarek MA Abdel-Fatah et al
5)
Metabolic reprogramming of ER+ breast cancer cells in response and resistance to the CDK4/6 inhibitor palbociclib Nicla Lorito et al
Managing the axilla
CAN WE COMPLETELEY AVOID AXILLARY SURGERY FOR SOME BREAST CANCER PATIENTS?
Monica Morrow
UK GUIDELINES FOR MANAGEMENT OF THE AXILLA POST-NACT
Julie Doughty
MODERN ROLE OF THE RADIOLOGIST IN MANAGING THE AXILLA
Anthony Maxwell
CHAIRS: Andreas Makris & Mark Sibbering
Dr Monica Morrow
Dr Anthony Maxwell
Miss Julie Doughty
Late recurrence in ER+ disease
LATE RECURRING ER+ GENOMIC SUBGROUPS
Carlos Caldas
Predicting late recurrence, patient, tissue and circulating factors
Nicholas Turner
PREVENTING LATE RECURRENCE
Ian Smith
CHAIRS: Adrian Lee & Mark Harries
Professor Nicholas Turner
Professor Carlos Caldas
Professor Ian Smith
Improving breast cancer outcomes by modifying lifestyle
OBESITY AND BREAST CANCER RISK
Annie Anderson
DIET BEFORE AND AFTER A DIAGNOSIS OF BREAST CANCER AND OUTCOME
Michelle Harvie
EFFECTS OF EXERCISE/PHYSICAL ACTIVITY ON OUTCOMES AFTER A BREAST CANCER DIAGNOSIS
Anna Campbell
CHAIRS: Mairead Mackenzie & Liz O’Riordan
Professor Annie Anderson
Professor Anna Campbell
Dr Michelle Harvie
Novel clinical trial design
BREAST CANCER TRIALS: CREATING DESIGNS FIT FOR CONTEMPORARY QUESTIONS
Judith Bliss
CAN BAYESIAN ADAPTIVE TRIALS BE USEFUL IN BREAST CANCER?
James Wason
PRESURGICAL WINDOW STUDIES OF NOVEL DRUGS – WHAT’S THE END-POINT?
Adrian Harris
CHAIRS: Judith Bliss & Alistair Ring
Professor Adrian Harris
Professor James Wason
Professor Judith Bliss
Keynote Lecture: Eric Winer
CRIDLAN LECTURE
DE-ESCALATION OF MEDICAL ADJUVANT THERAPY
CHAIR: Gill Ross
Professor Eric Winer
18:15-19:15
Drinks reception and poster judging (Session 1)
08:00-09:00
Exhibition Hall
Keynote Lecture: Martine Piccart
SUCCESSES, DISAPPOINTMENTS AND THE FUTURE FOR CLINICAL TRIALS IN PRIMARY BREAST CANCER
CHAIR: Judith Bliss
Dr Martine Piccart
Modernising breast MDT meetings
IMPROVING MDTM EFFICIENCY – THE DEVELOPMENT OF A MULTIDISCIPLINARY TOOLKIT
Mark Sibbering
MULTIDISCIPLINARY PANEL DISCUSSION
Charlotte Coles; Katy Hogben; Sue Holcombe; Sarah Pinder; Sarah Vinnicombe; Andrew Wardley
INTERACTIVE MDT CASE DISCUSSIONS
Nicola Roche
CHAIRS: Mark Sibbering and Debbie Fenlon
Katy Hogben
Mrs Sue Holcombe
Miss Nicola Roche
Mr Mark Sibbering
Professor Andrew Wardley
Professor Charlotte Coles
Professor Sarah Pinder
Dr Sarah Vinnicombe
Immune therapy
TREATMENT RESPONSE AND TOXICITIES IN BREAST CANCER
Mark Harries
COMBINED ANALYSIS OF PDL1 AND TILs IN BREAST CANCER: THE NEW NARRATIVE IN DAILY PRACTICE?
Roberto Salgado
CHARACTERISING IMMUNE RESPONSE
Raza Ali
CHAIRS: Andrew Tutt & Adrienne Morgan
Dr Raza Ali
Dr Roberto Salgado
Dr Mark Harries
Modelling breast cancer – moving closer to the clinic
HORMONES AND BREAST CANCER – WHY MODELS MATTER
Cathrin Brisken
A NEW 3D MODEL FOR BREAST CANCER – ALTERNATIVES TO XENOGRAFTS AND PDX
Gillian Farnie
THE CHALLENGES OF MEASURING THE RESPONSE TO IMMUNOTHERAPIES IN VIVO
Jonas Nillson
CHAIRS: Ingunn Holen & Rob Clarke
Professor Cathrin Brisken
Professor Jonas Nillson
Trials in progress
Multidisciplinary aspects of clinical trials
SMALL: DR Nisha Sharma
POSNOC and ATNEC: Dr Duncan Wheatley
PRIMETIME: Cliona Kirwan
OPTIMA: Dr Andreas Makris
POETIC -A: Dr Alistair Ring
CHAIRS: Dan Rea & Carlo Palmieri
Dr Alistair Ring
Professor Cliona Kirwan
Dr Andreas Makris
Breast Cancer Risk and Prevention
RECENT LESSIONS FROM THE WHI STUDY
Rowan Chlebowski
CHEMOPREVENTION OF BREAST CANCER – WHERE HAVE WE GOT TO?
Jack Cuzick
LOW-DOSE TAMOXIFEN FOR BREAST CANCER PREVENTION
Andrea De Censi
CHAIRS: Trevor Powles & Anne Armstrong
Dr Andrea De Censi
Prognostic and Predictive Profiling
PREDICT VS NPI
Paul Pharoah
CAN MRNA REPLACE IHC FOR ER?
Adrian Lee
KI67 – WILL IT EVER MAKE IT? A REPORT OF 10 YEARS’ WORK FROM THE INTERNATIONAL KI67 IN BREAST CANCER WORKING GROUP
Mitch Dowsett
CHAIRS: Kieran Horgan & Steffi Oesterreich
Professor Paul Pharoah
Dr Adrian Lee
Professor Mitch Dowsett
Special issues in managing young patients
CHOOSING ENDOCRINE TREATMENT
Daniel Rea
MANAGING FERTILITY IN BREAST CANCER
Melanie Davies
PREGNANCY AFTER BREAST CANCER
Sibylle Loibl
CHAIRS: Andrew Wardley & Liz O’Riordan
Dr Melanie Davies
Professor Sibylle Loibl
Professor Daniel Rea
11:55-13:10
Hall 11
Free Communications: 2
Chairs: Andy Sims & David Miles
1)
Pathological features and outcome of screen detected ductal carcinoma in situ (DCIS): Updated analysis from the UK Sloane Project
Abeer M Shaaban et al
2)
Fulvestrant plus capivasertib versus placebo in metastatic ER positive breast cancer (FAKTION): A randomised, double-blind, placebo-controlled, phase II trial
Sacha Jon Howell et al
3)
Results from plasmaMATCH: A multiple parallel cohort, multi-centre clinical trial of circulating tumour DNA testing to direct targeted therapies in patients with advanced breast cancer
Alistair Ring et al
4)
Whole-genome-sequencing of triple negative breast cancers in a standard population-based clinical setting Johan Staaf et al
5)
A 3D-printed electrochemical sensor for measuring reactive oxygen/nitrogen species production from breast cancer cells and ex vivo-cultured tumour tissue
William E Jones et al
13:15-14:15
Hall 8
SATELLITE SYMPOSIA: LILLY
Chair:
• Dr Marina Parton, Consultant Medical Oncologist, Royal Marsden NHS Foundation Trust
Panel:
• Professor David Cameron, Professor of Medical Oncology, Cancer Research UK Edinburgh Centre
• Suzanne Frank, Advanced Specialist Breast Cancer Pharmacist, The Christie NHS Foundation Trust
• Dr Judy King, Consultant Medical Oncologist, Royal Free London NHS Foundation Trust
• Maria Noblet, Consultant Nurse in Breast Cancer, Portsmouth Hospitals NHS Trust
• Dr Duncan Wheatley, Clinical Oncologist, Royal Cornwall Hospitals NHS Trust
Welcome and introduction
Overview of the mBC treatment landscape and emergence of CDK4/6 inhibitors Dr Marina Parton (Chair)
A case in point: benefit in bone metastases*
Case presentation, audience voting and panel discussion Dr Judy King
Panel discussion
A case in point: leveraging CDK4 & 6 inhibitors in liver lesions*
Case presentation, audience voting and panel discussion Professor David Cameron
Panel discussion
A case in point: defying primary endocrine resistance*
Case presentation, audience voting and panel discussion
Abemaciclib overall survival data presentation Dr Duncan Wheatley
Panel discussion
Summary and close Dr Marina Parton (Chair)
*Educational topics including scheduling treatments and managing toxicities discussed within the case studies.
13:15-14:15
Hall 11
SATELLITE SYMPOSIA: DAIICHI SANKYO
Challenges in Biomarker interpretation in the real world – An MDT discussion
Panellists:
Professor Dan Rea (chair)
Dr Rebecca Roylance
Mr Stuart McIntosh
Dr Abeer Shaaban
Professor Christopher Poole
13:15 - 14:15
Hall 5
SATELLITE SYMPOSIA: NANOSTRING
Identifying Breast Cancer Biomarkers for Understanding Heterogeneity of Response
Speaker: Rudy van Eijsden, Senior Product Application Scientist NanoString
Using the NanoString nCounter® and GeoMx™ DSP platforms to advance breast cancer research.
Speaker: Dr Sheeba Irshad CRUK Clinician Scientist & Honorary Medical Oncologist Guy’s Hospital King’s College London, UK
Investigating the immune landscape of chemotherapy resistant early breast cancers
14:20-14:25
Hall 1
Keynote Lecture: Monica Morrow
DE-ESCALATING SURGERY FOR BREAST CANCER
CHAIR: Julie Doughty
Dr Monica Morrow
Special issues for elderly patients
SPECIAL ISSUES ON OLDER PATIENTS WITH PRIMARY BREAST CANCER
KL Cheung
BRIDGING THE AGE GAP
Lynda Wyld
DEMENTIA AND DECISION MAKING
Yasmin Jauhari
CHAIRS: KL Cheung & Alistair Ring
Dr Yasmin Jauhari
Professor Kwok-Leung Cheung
Professor Lynda Wyld
Minimising mastectomy
NEOADJUVANT CHEMOTHERAPY
Sibylle Loibl
BREAST CONSERVING SURGERY FOR MULTIFOCAL TUMOURS
Mike Dixon
ONCOPLASTIC SURGERY
Katy Hogben
CHAIRS: Julie Doughty & Andreas Makris
Katy Hogben
Professor Sibylle Loibl
Professor Mike Dixon
Translating new therapeutic opportunities
TARGETING CDK7 IN ER+ BREAST CANCER
Simak Ali
ANDROGEN RECEPTOR AGONISTS FOR AR+ DISEASE
Carlo Palmieri
PROSPECTS FOR TARGETING FOXA1
Jason Carroll
CHAIRS: Rob Clarke & Adrian Harris
Professor Carlo Palmieri
Professor Simak Ali
Professor Jason Carroll
Young Clinical Leaders
TRAINEE COLLABORATIVE RESEARCH – A SUCCESSFUL NEW STORY
Cliona Kirwan
THE ACHIEVEMENTS OF THE MAMMARY FOLD COLLABORATIVE AND CURRENT PROJECTS
Lisa Sheehan
MULTIDISCIPLINARY COLLABORATION – INTRODUCTION TO THE BCTRCG
Ellen Copson
DRAGON’S DEN
Tim Robinson
Sheeba Irshad
Teo Pei Jing
ACADEMIC CAREER PATHWAYS
Cliona Kirwan
WHY AND HOW TO JOIN A TRIAL MANAGEMENT GROUP
Indrani Bhattacharya
Chairs: Cliona Kirwan and Ellen Copson
Dr Pei Jing Teo
Professor Cliona Kirwan
Dr Ellen Copson
Dr Lisa Sheehan
Dr Indrani Bhattacharya
16:55
Hall 1